Vir Biotechnology, Inc. (VIR)
VIR Stock Price Chart
Explore Vir Biotechnology, Inc. interactive price chart. Choose custom timeframes to analyze VIR price movements and trends.
VIR Company Profile
Discover essential business fundamentals and corporate details for Vir Biotechnology, Inc. (VIR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2019
Employees
408.00
Website
https://www.vir.bioCEO
Marianne De Backer
Description
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Financial Timeline
Browse a chronological timeline of Vir Biotechnology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.33, while revenue estimate is $135.88m.
Earnings released on 6 May 2026
EPS came in at -$0.85 falling short of the estimated -$0.01 by -8.40k%, while revenue for the quarter reached -$29.00k , missing expectations by -100.05%.
Earnings released on 23 Feb 2026
EPS came in at -$0.31 surpassing the estimated -$0.42 by +26.19%, while revenue for the quarter reached $64.07m , beating expectations by +221.87%.
Earnings released on 5 Nov 2025
EPS came in at -$1.17 falling short of the estimated -$0.70 by -67.14%, while revenue for the quarter reached $240.00k , missing expectations by -98.79%.
Earnings released on 6 Aug 2025
EPS came in at -$0.80 falling short of the estimated -$0.72 by -11.11%, while revenue for the quarter reached $1.21m , missing expectations by -55.40%.
Earnings released on 7 May 2025
EPS came in at -$0.88 falling short of the estimated -$0.83 by -6.02%, while revenue for the quarter reached $1.79m , missing expectations by -79.12%.
Earnings released on 26 Feb 2025
EPS came in at -$0.76 surpassing the estimated -$0.85 by +10.59%, while revenue for the quarter reached $12.37m , beating expectations by +52.01%.
Earnings released on 31 Oct 2024
EPS came in at -$1.56 falling short of the estimated -$0.96 by -62.50%, while revenue for the quarter reached $2.38m , missing expectations by -74.59%.
Earnings released on 1 Aug 2024
EPS came in at -$1.02 falling short of the estimated -$0.93 by -9.68%, while revenue for the quarter reached $3.08m , missing expectations by -59.00%.
Earnings released on 2 May 2024
EPS came in at -$0.48 surpassing the estimated -$0.99 by +51.52%, while revenue for the quarter reached $56.38m , beating expectations by +381.43%.
Earnings released on 22 Feb 2024
EPS came in at -$0.86 surpassing the estimated -$1.14 by +24.56%, while revenue for the quarter reached $16.79m , beating expectations by +25.00%.
Earnings released on 2 Nov 2023
EPS came in at -$1.22 falling short of the estimated -$1.21 by -0.83%, while revenue for the quarter reached $4.10m , missing expectations by -59.98%.
Earnings released on 3 Aug 2023
EPS came in at -$1.45 falling short of the estimated -$1.21 by -19.83%, while revenue for the quarter reached $12.72m , missing expectations by -50.86%.
Earnings released on 4 May 2023
EPS came in at -$1.06 falling short of the estimated -$0.81 by -30.86%, while revenue for the quarter reached $46.71m , missing expectations by -6.76%.
Earnings released on 23 Feb 2023
EPS came in at -$0.76 falling short of the estimated -$0.39 by -92.41%, while revenue for the quarter reached $21.79m , missing expectations by -85.44%.
Earnings released on 3 Nov 2022
EPS came in at $1.30 surpassing the estimated -$0.21 by +719.05%, while revenue for the quarter reached $371.43m , beating expectations by +225.20%.
Earnings released on 9 Aug 2022
EPS came in at -$0.58 falling short of the estimated -$0.17 by -241.18%, while revenue for the quarter reached $42.69m , missing expectations by -78.73%.
Earnings released on 5 May 2022
EPS came in at $3.85 surpassing the estimated $3.78 by +1.85%, while revenue for the quarter reached $1.23bn , beating expectations by +51.65%.
Earnings released on 24 Feb 2022
EPS came in at $3.92 surpassing the estimated $3.04 by +28.95%, while revenue for the quarter reached $809.76m , beating expectations by +29.99%.
Earnings released on 4 Nov 2021
EPS came in at $0.82 surpassing the estimated $0.02 by +3.49k%, while revenue for the quarter reached $102.71m , missing expectations by -2.30%.
Earnings released on 5 Aug 2021
EPS came in at $0.46 surpassing the estimated -$0.48 by +195.83%, while revenue for the quarter reached $173.99m , beating expectations by +105.75%.
VIR Stock Performance
Access detailed VIR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
